Arlene Reisman

4.9k citations
54 papers · 3.6k indexed · 2 hit papers · h-index 17
Topics
Lung Cancer Treatments and Mutations (18 papers)Lung Cancer Diagnosis and Treatment (13 papers)Chronic Lymphocytic Leukemia Research (10 papers)
Partner nations
United StatesItalyCanada

In The Last Decade

Arlene Reisman

51 papers receiving 3.5k citations

Hit Papers

First-Line Crizotinib versus Chemotherapy in ALK-Positive...20122026201620212014201250010001.5k2.0k

Peers

Arlene Reisman
Comparison fields: 5 of 104
  • Pulmonary and Respiratory Medicine 2.3k
  • Oncology 1.9k
  • Molecular Biology 755
  • Cancer Research 631
  • Infectious Diseases 544
Replace Gary Dukart with:
Gary Dukart United States
Raghunadharao Digumarti India
Ji Yun Lee South Korea
Jennie R. Crews United States
Erin B. Kennedy United States
Giorgio Ercolani Italy
Federico Vázquez Spain
Raymond Aerts Belgium
Emmanuel Raffoux France
Erin Jensen United States
Arlene Reisman relative to Gary Dukart United States Gary Dukart's profile →
Citations per field
00.5×3.6×
Gary Dukart · 1×
Citations per year

Countries citing papers authored by Arlene Reisman

Since Specialization
Citations

This map shows the geographic impact of Arlene Reisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arlene Reisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arlene Reisman more than expected).

Fields of papers citing papers by Arlene Reisman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arlene Reisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arlene Reisman. The network helps show where Arlene Reisman may publish in the future.

Co-authorship network of co-authors of Arlene Reisman

This figure shows the co-authorship network connecting the top 25 collaborators of Arlene Reisman. A scholar is included among the top collaborators of Arlene Reisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arlene Reisman. Arlene Reisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 4
2 0
3 23
4 9
5 15
6 1
7 82
8 3
9 2
10 58
11
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancerbreakdown →
2327
12 1
13 25
14
Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Studybreakdown →
402
15 25
16 78
17 72
18 30
19 10
20 11

About Arlene Reisman

Arlene Reisman is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine, having authored 54 papers that have together received 3.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.3k citations), Oncology (1.9k citations) and Cancer Research (631 citations). Arlene Reisman has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Shrividya Iyer, Keith D. Wilner, Benjamin Solomon, Fiona Blackhall, Tony Mok, Enriqueta Felip, Dong‐Wan Kim, Jolanda Paolini, Yi‐Long Wu and Tarek Mekhail. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026